A phase 2 study of maridebart cafraglutide (MariTide, Amgen), an investigational injectable GLP-1 receptor agonist/GIP receptor antagonist, showed a significant weight loss of approximately 20% at 1 year in patients with overweight or obesity. Importantly, this weight loss did not plateau, and the drug also improved key cardiometabolic parameters, such as systolic blood pressure and LDL cholesterol. The second part of the study, evaluating patients who lost at least 15% of their body weight, is currently ongoing.
Osteoporosis Prevalence High for All Races, Incomes Undergoing Lung Cancer Screening
Osteoporosis is highly prevalent among individuals undergoing lung cancer screening, regardless of race, ethnicity, or income. CT scans combined with an AI-based tool were found to be effective in detecting osteoporosis and body composition in these patients without additional radiation or testing. This non-invasive approach could provide an important diagnostic tool for those undergoing lung cancer treatment.
Younger Age at Type 2 Diabetes Diagnosis Tied to Higher Dementia Risk
A study published in PLOS One found a significant association between a younger age at diagnosis of type 2 diabetes and an increased risk of developing dementia, particularly in individuals with obesity. This highlights the importance of early intervention and management in individuals diagnosed with diabetes at a younger age.
The Year in Obesity: New Data on Semaglutide and Tirzepatide, Sarcopenic Obesity, and More
Recent findings on semaglutide and tirzepatide revealed that these medications offer benefits beyond glucose and weight reduction. These drugs may have additional effects that could improve overall health outcomes, particularly in the context of sarcopenic obesity, a condition characterized by muscle loss and obesity.
Related topics:
Eggplant Tests Blood Sugar “Prick What?
Eat This Before Meals. It Really Helps Control Your Blood Sugar!
Double C” Care and Free Health Assessments Help Haibei Diabetics Manage Blood Sugar
